Abstract
In chemical risk assessment, default uncertainty factors are used to account for interspecies and interindividual differences, and differences in toxicokinetics and toxicodynamics herein. However, these default factors come with little scientific support. Therefore, our aim was to develop an in vitro method, using acetylcholinesterase (AChE) inhibition as a proof of principle, to assess both interspecies and interindividual differences in toxicodynamics. Electric eel enzyme and human blood of 20 different donors (12 men/8 women) were exposed to eight different compounds (chlorpyrifos, chlorpyrifos-oxon, phosmet, phosmet-oxon, diazinon, diazinon-oxon, pirimicarb, rivastigmine) and inhibition of AChE was measured using the Ellman method. The organophosphate parent compounds, chlorpyrifos, phosmet and diazinon, did not show inhibition of AChE. All other compounds showed concentration-dependent inhibition of AChE, with IC50s in human blood ranging from 0.2–29 µM and IC20s ranging from 0.1–18 µM, indicating that AChE is inhibited at concentrations relevant to the in vivo human situation. The oxon analogues were more potent inhibitors of electric eel AChE compared to human AChE. The opposite was true for carbamates, pointing towards interspecies differences for AChE inhibition. Human interindividual variability was low and ranged from 5–25%, depending on the concentration. This study provides a reliable in vitro method for assessing human variability in AChE toxicodynamics. The data suggest that the default uncertainty factor of ~ 3.16 may overestimate human variability for this toxicity endpoint, implying that specific toxicodynamic-related adjustment factors can support quantitative in vitro to in vivo extrapolations that link kinetic and dynamic data to improve chemical risk assessment.
Highlights
Acetylcholinesterase (AChE) is an important enzyme in the nervous system and a common target of toxicity
Besides its importance for the nervous system, AChE is present in the blood, where it is involved in the nitric oxide signal pathway (Saldanha 2017)
The aims of this study are: (1) to measure the inhibition of AChE using eight different compounds, (2) to assess interspecies differences in AChE inhibition by comparing electric eel and human AChE, (3) to assess human variability in both baseline activity and inhibition of AChE activity for future integration in physiologically based kinetic/dynamic models accounting for variability in both kinetics and dynamics
Summary
Acetylcholinesterase (AChE) is an important enzyme in the nervous system and a common target of toxicity. Like carbamates (e.g. pirimicarb and carbaryl) can bind reversibly to AChE and can cause the same types of (clinical) symptoms as OP-poisoning, but. AChE is inhibited by pharmaceutical carbamates like rivastigmine, which is used in the treatment of Alzheimer’s disease (Pinho et al 2013). Besides its importance for the nervous system, AChE is present in the blood, where it is involved in the nitric oxide signal pathway (Saldanha 2017). Multiple studies confirm that there is a high functional similarity between the two and that measuring blood AChE activity is a fast and easy way to assess AChE activity in the nervous system (Duncan and Griffith 1992; Worek et al 2012)
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have